News
LPCN
1.480
-1.33%
-0.020
Weekly Report: what happened at LPCN last week (1109-1113)?
Weekly Report · 4d ago
Lipocine doses first patient in Phase 3 study evaluating LPCN 1154
TipRanks · 11/10 16:33
Lipocine Initiates Phase 3 BLOOM Study for Postpartum Depression
TipRanks · 11/10 11:32
Weekly Report: what happened at LPCN last week (1102-1106)?
Weekly Report · 11/09 09:53
Lipocine Inc. Reports Third Quarter of 2026 Financial Results and Initiates Phase 3 BLOOM Study
NASDAQ · 11/06 05:28
Press Release: Lipocine Announces Financial -2-
Dow Jones · 11/05 13:00
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
NASDAQ · 11/03 21:15
Weekly Report: what happened at LPCN last week (1026-1030)?
Weekly Report · 11/02 09:53
Weekly Report: what happened at LPCN last week (1019-1023)?
Weekly Report · 10/26 09:53
Lipocine Updates Investor Presentation to Reflect Strategy
TipRanks · 10/20 12:17
Weekly Report: what happened at LPCN last week (1012-1016)?
Weekly Report · 10/19 09:52
Weekly Report: what happened at LPCN last week (1005-1009)?
Weekly Report · 10/12 09:56
3 Penny Stocks to Watch Today, October 8
TipRanks · 10/08 13:28
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
Benzinga · 10/07 16:02
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Benzinga · 10/07 14:44
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
Benzinga · 10/07 13:52
Lipocine Jumps On TLANDO's Health Canada Approval For Testosterone Replacement Therapy
NASDAQ · 10/07 13:50
Lipocine announces Health Canada approved TLANDO capsules
TipRanks · 10/07 12:11
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/07 12:05
Lipocine’s TLANDO Wins Health Canada Approval
TipRanks · 10/07 10:30
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.